Common use of PRICE AND PAYMENT SCHEDULE Clause in Contracts

PRICE AND PAYMENT SCHEDULE. Any costs or expenses not specified in the Agreement or changes to the budget must be approved in advance in writing by the Sponsor or CRO. Without such approval, the Sponsor or CRO will not pay any additional costs, expenses or changes in budget. All fees set out below are exclusive of VAT. Insert agreed budget table For subjects who do not complete the study, payment will be made on a pro-rata basis according to the number of visits attended, depending upon the reason for withdrawal being satisfactorily documented. The Sponsor or XXX agrees to reimburse all reasonable subject travel expenses. The Clinical Organisation will retain records of journeys made by subjects including receipts of travel if applicable. Payment of the amounts due under this Agreement is subject to: The Clinical Trial being completed in accordance with the Protocol The Clinical Organisation providing to the Sponsor or CRO all requested documentation/receipts for expenses; and The Principal Investigator complying with the terms of this Agreement. Payment will be made when the data has been entered onto the EDC system and on submission of a valid invoice to the Sponsor or CRO by the Clinical Organisation. All invoices relating to the Agreement and subsequent amendments must quote the following information XXXXXXXXXXXX. Invoices which do not display a valid information number cannot be processed for payment and will be returned to the Clinical Organisation disputed. The address stated on the invoice must be: XXXXXXXXXXXX In order for invoices to be processed without delay, please ensure that invoices are emailed in an unzipped PDF format (1 invoice per email, quote purchase order number in subject line) to our Accounts Payable Department at Vendor Registered Name Vendor Address EIR Code Phone Fax Email address VAT Registration number Bank Name Bank Address Account Number IBAN Code The Principal Investigator is free to participate in the Clinical Trial and there are no rights that may be exercised by, or obligations owed to, any third party that may prevent or restrict the performance by the Principal Investigator of the obligations set out in the Agreement. The Principal Investigator is not the subject of any regulatory litigation or misconduct litigation or investigation. No data produced by the Principal Investigator in any other clinical trial has been rejected because of concerns as to its accuracy or because it was generated by fraudulent means. The Principal Investigator has considered and is satisfied that facilities appropriate to the Clinical Trial are available at the Clinical Organisation and that in the performance of obligations under this Agreement, is satisfied that he/she will be supported by medical and other staff of sufficient number and experience to enable the Clinical Organisation to perform the Clinical Trial efficiently and in accordance with the obligations under this Agreement. During the Clinical Trial, the Principal Investigator will not serve as principal investigator or sub-investigator in any clinical trial for another sponsor if such activity may adversely affect the ability of the Principal Investigator to perform his/her obligations under this Agreement. Appendix 4 – Material Transfer Provisions Where the Protocol requires the Clinical Organisation to supply Material to the Sponsor or CRO this Appendix 4 shall apply. In accordance with the Protocol, the Clinical Organisation shall send Material to the Sponsor, CRO or, in accordance with Section 7 below, to a third party nominated by the Sponsor or CRO. The Clinical Organisation will arrange for the signed informed consent approved by the Principal Investigator, the Sponsor and HRPA/ethics committee for the collection of Materials to be signed by the Clinical Trial Subject and shall collect and handle the Materials in accordance with such consent, applicable law (including, without limitation, Statutory Instrument No. 158 of 2006 (Quality and Safety of Human Tissues and Cells) Regulations) and as required by the Protocol. Subject to Section 2 above, the Material is supplied without any warranty, expressed or implied, including as to its properties, merchantable quality, fitness for any particular purpose, or freedom from infection. The Sponsor or CRO shall ensure, or procure through an agreement with the nominee of the Sponsor or CRO as stated in item 1 above, that:

PRICE AND PAYMENT SCHEDULE. Any costs or expenses not specified in the Agreement or changes to the budget must be approved in advance in writing by the Sponsor or CROSponsor. Without such approval, the Sponsor or CRO will not pay any additional costs, expenses or changes in budget. All fees set out below are exclusive of VAT. Insert agreed budget table For subjects who do not complete the study, payment will be made on a pro-rata basis according to the number of visits attended, depending upon the reason for withdrawal being satisfactorily documented. The Sponsor or XXX agrees to reimburse all reasonable subject travel expenses. The Clinical Organisation will retain records of journeys made by subjects including receipts of travel if applicable. Payment of the amounts due under this Agreement is subject to: The Clinical Trial being completed in accordance with the Protocol The Clinical Organisation providing to the Sponsor or CRO all requested documentation/receipts for expenses; and The Principal Investigator complying with the terms of this Agreement. Payment will be made when the data has been entered onto the EDC system and on submission of a valid invoice to the Sponsor or CRO by the Clinical Organisation. All invoices relating to the Agreement and subsequent amendments must quote the following information XXXXXXXXXXXX. Invoices which do not display a valid the required information number cannot be processed for payment and will be returned to the Clinical Organisation disputedOrganisation. The address stated on the invoice must be: XXXXXXXXXXXX In order for invoices to be processed without delay, please ensure that invoices are emailed in an unzipped PDF format (1 invoice per email, quote purchase order Protocol number in subject line) to our Accounts Payable Department at at: [Insert address] Vendor Registered Name Vendor Address EIR Code Phone Fax Email address VAT Registration number Bank Name Bank Address Account Number IBAN Code The Principal Investigator is free to participate in the Clinical Trial and there are no rights that may be exercised by, or obligations owed to, any third party that may prevent or restrict the performance by the Principal Investigator of the obligations set out in the Agreement. The Principal Investigator is not the subject of any regulatory litigation or misconduct litigation or investigation. No data produced by the Principal Investigator in any other clinical trial has been rejected because of concerns as to its accuracy or because it was generated by fraudulent means. The Principal Investigator has considered and is satisfied that facilities appropriate to the Clinical Trial are available at the Clinical Organisation and that in the performance of obligations under this Agreement, is satisfied that he/she will be supported by medical and other staff of sufficient number and experience to enable the Clinical Organisation to perform the Clinical Trial efficiently and in accordance with the obligations under this Agreement. During the Clinical Trial, the Principal Investigator will not serve as principal investigator or sub-investigator in any clinical trial for another sponsor if such activity may adversely affect the ability of the Principal Investigator to perform his/her obligations under this Agreement. Appendix 4 – Material Transfer Provisions Where the Protocol requires the Clinical Organisation to supply Material to the Sponsor or CRO this Appendix 4 shall apply. In accordance with the Protocol, the Clinical Organisation shall send Material to the Sponsor, CRO or, in accordance with Section 7 below, to a third party nominated by the Sponsor or CRO. The Clinical Organisation will arrange for the signed informed consent approved by the Principal Investigator, the Sponsor and HRPA/ethics committee for the collection of Materials to be signed by the Clinical Trial Subject and shall collect and handle the Materials in accordance with such consent, applicable law (including, without limitation, Statutory Instrument No. 158 of 2006 (Quality and Safety of Human Tissues and Cells) Regulations) and as required by the Protocol. Subject to Section 2 above, the Material is supplied without any warranty, expressed or implied, including as to its properties, merchantable quality, fitness for any particular purpose, or freedom from infection. The Sponsor or CRO shall ensure, or procure through an agreement with the nominee of the Sponsor or CRO as stated in item 1 above, that:.